Skip to Content

Symposia on Cancer Research 2010: Personalized Cancer Therapy and Prevention

October 8-9, 2010

The University of Texas MD Anderson Cancer Center
R. Lee Clark Clinic
11th Floor
1515 Holcombe Boulevard
Houston, Texas

General Information

Focus

This Symposium on Cancer Research will bring together internationally recognized scientists from academia, industry, regulatory agencies, as well as patient advocates to describe and discuss state-of-the-art approaches to bringing personalized approaches to cancer therapy. Dr. David Sidransky (Johns Hopkins School of Medicine) will present the keynote address. In addition, Dr. Carlo Croce (Ohio State University) will receive the Ernst W. Bertner Memorial Award, and Dr. Leroy Hood (Institute for Systems Biology) will receive the Heath Memorial Award. There will also be a poster session for participants to present their research findings. The symposium begins on Friday morning and ends on Saturday afternoon.

Goal

Personalized medicine is the use of genetic markers and/or pharmacogenomic testing to tailor an individual’s preventative care or therapy. “The goal is personalized therapy that takes into account the genetics of the cancer and the patient.” - John Mendelsohn, MD, President. Top experts in the field will describe the latest progress towards this goal.

Target Audience

The program will be of broad interest to scientists, scientists-in-training, physicians, physicians-in-training, students, nurses, and fellows interested in hearing the newest advances in the area of personalized cancer therapy and prevention.

Educational Objectives

After attending the symposium, participants should be able to

  • Incorporate the latest research findings into their clinical practice;
  • Demonstrate new techniques in personalized cancer therapy and prevention;
  • Assess the role of biomarkers and targeted therapy in current clinical practice;
  • Recognize the convergence between prevention and treatment of cancer;
  • Identify the challenges and limitations to translating current genomic, proteomic information into clinical practice;
  • Identify the best preclinical model for specific applications and the advantages and limitations of specific models

Educational Methods

  • Lectures
  • Question-and-Answer Sessions
  • Panel Discussions
  • Posters

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Texas MD Anderson Cancer Center designates this educational activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates

Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.


© 2010 The University of Texas MD Anderson Cancer Center